Uterine myoma.
Conditions
Interventions
Sponsors
Eligibility
Inclusion criteria
Inclusion criteria: Non-menopausal women between the ages of 18 and 45, who have a myoma larger than 5 cm that have abnormal uterine bleeding, pelvic pain, dysmenorrhea, and a compressive effect. Women with myomas larger than or equal to 5 cm who have other myomas (s) less than 2 cm in size
Exclusion criteria
Exclusion criteria: Women with extra myoma (s) greater than or equal to 2 cm Women with uterine myoma who have been treated with any type of estrogen or progesterone in less than a month and hormonal implants in the last 3 months Women with a history of major medical illness and / or previous drug or surgical treatment of uterine leiomyomas All women with myomas 2-5 cm in size were excluded from the study Patients receiving antihypertensive drugs, beta-blockers and calcium channel blockers, and ACE inhibitors were excluded from the study due to possible drug interactions Patients who develop side effects during the study will be excluded from the study
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Uterine myoma size. Timepoint: At the beginning of the study and 6 and 12 weeks after starting treatment. Method of measurement: Vaginal ultrasound machine. | — |
Secondary
| Measure | Time frame |
|---|---|
| LH hormon. Timepoint: At the beginning of the study and 12 weeks after treatment. Method of measurement: RIA laboratory method.;FSH hormon. Timepoint: At the beginning of the study and 12 weeks after treatment. Method of measurement: RIA laboratory method.;Estradiol hormon. Timepoint: At the beginning of the study and 12 weeks after treatment. Method of measurement: RIA laboratory method. | — |
Countries
Iran (Islamic Republic of)
Contacts
Semnan University of Medical Sciences